Skip to main content
Kamada Ltd. logo

Kamada Ltd. — Investor Relations & Filings

Ticker · KMDA ISIN · IL0010941198 TA Manufacturing
Open in API
Filings indexed 829 across all filing types
Latest filing 2026-03-21 Director's Dealing
Country IL Israel
Listing TA KMDA

About Kamada Ltd.

https://www.kamada.com

Kamada Ltd. is a vertically integrated global biopharmaceutical company specializing in plasma-derived protein therapeutics. The company develops, manufactures, and commercializes a portfolio of products for rare and serious conditions, with a focus on therapeutic areas such as Alpha-1 Antitrypsin Deficiency (AATD) and Cytomegalovirus (CMV) prevention in transplant patients. Kamada utilizes a proprietary platform technology for advanced protein extraction and purification from human plasma. In addition to its marketed products, the company maintains a development pipeline of new therapies, including an inhaled treatment for AATD.

Recent filings

Filing Released Lang Actions
Other Report or Announcement
Director's Dealing Classification · 91% confidence The document is a United States SEC Form 3 ‘‘Initial Statement of Beneficial Ownership of Securities’’ filed under Section 16(a). It details the personal securities holdings (ordinary shares and options) of a company director (Benjamin Dekel). This falls squarely under insider reporting of director/executive share transactions. Therefore, it is classified as Director’s Dealing.
2026-03-21 English
Other Report or Announcement
Director's Dealing Classification · 91% confidence The document is an ISA/TASE announcement under Regulation 5, stating “Attached hereto is a report on Notification of a Form 3 filed with the SEC by Benjamin Dekel.” Form 3 is the initial insider statement of beneficial ownership for directors/executives. The announcement concerns an insider’s share transaction filing. Therefore, this is a Director’s Dealing notification. Code: DIRS.
2026-03-21 English
Other Report or Announcement
Director's Dealing Classification · 94% confidence The document is an SEC Form 3 “Initial Statement of Beneficial Ownership of Securities,” filed pursuant to Section 16(a) by a corporate insider (a director) detailing their personal stock and option holdings. This clearly falls under insider share transactions by directors and officers, which corresponds to our “Director’s Dealing” category.
2026-03-21 English
Other Report or Announcement
Director's Dealing Classification · 90% confidence The document is an immediate report under the Israeli periodic and immediate reporting regime, attaching a notification of a Form 3 filed with the U.S. SEC by an insider (Assaf Itshayek). Form 3 filings record insider share transactions or holdings. Therefore this is a director’s dealing / insider transaction report.
2026-03-21 English
Other Report or Announcement
Director's Dealing Classification · 90% confidence The document is an SEC Form 3 "Initial Statement of Beneficial Ownership of Securities", filed under Section 16(a) of the Securities Exchange Act. It discloses insider holdings and options of a company director/officer (Amir London). This matches the definition of Director's Dealing (Code: DIRS): a report of personal share transactions by company directors and executives.
2026-03-21 English
Other Report or Announcement
Director's Dealing Classification · 75% confidence The document is an immediate report filed via the Tel Aviv Stock Exchange (MAGNA) under Regulation 5. It announces and attaches a Form 3 filed with the US SEC by Amir London, which is an initial insider beneficial ownership report. Under our taxonomy, SEC insider filings (Form 3/4/5) are classified as Director’s Dealing (DIRS).
2026-03-21 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.